Our very thin CLL
Society team is busy preparing for the ASCO (American Society of Clinical
Oncology) 2015 Annual meeting which starts at the end of this week in Chicago,
but we still found time to bring three diverse and instructive new topics to
our website http://cllsociety.org for this week.
Today, Monday, May 25,
2015, we posted Dr. Adrian Wiestner's thoughtful and well-considered interview
from ASH (American Society of Hematology) 2014 on what is known and unknown
about novel therapies. You can find that here.
Expect more video
interviews and commentaries from ASH 2014 over the next several weeks.
On Wednesday, the
camera is turned on yours truly for my personal take on CLL topics of interest.
We include the short video and an updated transcript on this week's topic of
oral versus IV medications. I think you might be surprised at some of the
issues and non-issues in what would seem at first glance to be should be a
simple choice. I have posted extensively about the tragedies that were
associated with potent oral medications before we knew about the risk of tumor
lysis with ABT-199 now known as venetoclax or in the case of lenalidomide (Revlimid), where
there is also the risk of tumor flare. These risks have largely been mitigated
now with new dosing protocols. Please see this prior blog post
for part of the story.
This new section on the CLL Society website using
monologues and text will roll out here.
And this will be only
the first in a long series of instructional postings on the various CLL
On Friday, we will post
an up to the minute review of and link to an important ASCO 2105 abstract about
the latest data on combining idelalisib with chemo-immunotherapy. You will find
it here on Friday.
Please let us know what
you think, especially about my reading and the transcripts of my monologues.
You can contact the CLL Society here or email directly, but the 1st method
We are constantly
working to respond to the unmet needs of the CLL community, so we listen
carefully to what you write us and try to respond as best we can.
We don't have a big
production budget and team or large institutional backing, but we keep going to
offer up the most robust and recent, yet still accessible information with no
gloss and no agenda other than to inform our community.
Because we believe that
SMART PATIENTS GET SMART CARE™
Switching to a personal
update, my wife and I are stilling struggling with a lingering upper
respiratory infection aka a cold that my beautiful granddaughter shared when
visiting from Chicago. No fever or cough for me. With the frequent use of a Neti
pot, normal saline and steroid nasal sprays and a single shot of a decongestant
(and no antibiotics), I have managed to control the symptoms and survive the
pressure changes in the first of several air flights. Both of us remain “under the weather” after a
full week of symptoms, but we are slowly improving.
For most of my
immune-competent patients, I would never recommend an antibiotic in such
circumstances, but I am not most patients and either are any of my fellow
CLLers. We are all immune comprised. Our immune systems are as dysfunctional as
hyperactive adolescents who are asked to focus on a single boring multi-step
math problem while the rest of the vibrant world pours on around them. Like
those teenagers, my immunity’s focus is weak and easily diverted to the wrong
target, having lead in the past to my nasty autoimmune problem of ITP.
Tomorrow I am at Ohio
State for my three-month follow up on my ibrutinib trial.
Expecting another good
lab report. Usually my neutrophils jump up when I am sick at all, even with a
I wonder if Dr. Byrd will add an antibiotic and chide me for treating myself,
always an ill-advised choice.
Personal confession: I
worry about my admittedly relatively mild added illness. Worrying is already too
easy to do with CLL, and even more so when we are sick. URIs can lead to chest
infections and pneumonia is still the leading cause of mortality in CLL.
I will be much happier
when this infection is gone.
I will be home one day
this week, long enough to get my every 6 week dose of IVIG.
Late in the week, I
will be Orlando for less than 24 hours to lecture on anemia and gout to some
400 primary care providers. Then I fly onto Chicago for the very busy ASCO
(American Society of Clinical Oncology) Annual meeting.
Rest is not in the
picture. But it is a good busy and I will be with friends everywhere I travel.
I may even get to see
the little girl who gave me the cold in Chicago. If we are both well.
We are all in this
Volunteer Medical Director of the CLL Society
Labels: ABT-199, ASH 2014, Chronic lymphocytic leukemia, Clinical Trial, CLL, Dr. Adrian Wiestner, Head cold, Idelalisib, Lenalidomide, OSU, venetoclax